AstraZeneca Unveils Two U.S. Approvals Spanning Bladder Cancer and Rare Disease

One approval could reset care for bladder-cancer patients who cannot take standard chemotherapy; the other competes on convenience in a crowded rare-disease market.

Sources

Sources & evidence

What “Source checked” means

AZNLatest quote

AstraZeneca announced two U.S. approvals on Monday: a bladder-cancer regimen that cut the risk of death in a late-stage trial, and a weekly self-injected treatment for a rare muscle-weakening disease.

AstraZeneca announced the two United States approvals together on Monday, November 16. The Food and Drug Administration (FDA) approved the Imfinzi bladder regimen on Friday, November 13.

A survival benefit in bladder cancer

The Imfinzi approval covers adults with muscle-invasive bladder cancer (MIBC), where the tumor has grown into the bladder wall muscle. It applies to patients ineligible for, or refusing, cisplatin-based chemotherapy.

The regimen gives Imfinzi with enfortumab vedotin-ejfv before surgery, a step called neoadjuvant treatment. After radical cystectomy, surgery to remove the bladder, patients receive Imfinzi alone as adjuvant treatment.

Patients receive three cycles before surgery, then nine cycles of Imfinzi alone afterward. The FDA dosage sets Imfinzi at 1,500 milligrams every three weeks before surgery, then every four weeks.

Enfortumab vedotin-ejfv is dosed at 1.25 milligrams per kilogram on days 1 and 8 of each cycle. The FDA granted Priority Review, acted under Project Orbis, and approved six weeks ahead of its goal date.

What the VOLGA trial showed

The approval rests on VOLGA, a Phase III trial that randomized 695 patients across three arms. One arm tested the approved two-drug regimen, one added an investigational third drug, and one was the comparator.

Event-free survival, the time without progression, recurrence, missed surgery or death, improved sharply. The hazard ratio was 0.51, a 49% reduction in risk, and median event-free survival was not reached, against 12.1 months for surgery alone.

An estimated 64% of combination patients were alive and event-free at two years, against 45% on the comparator. Overall survival also favored the regimen, with a hazard ratio of 0.58, a 42% reduction in the risk of death.

Median overall survival was not reached in either arm at the planned interim analysis. An estimated 78% of combination patients were alive at two years, against 69% on the comparator.

Grade 3 and 4 adverse events, the severe categories, occurred in 64% of combination patients and 44% of comparators. AstraZeneca reported no new safety signals, and patient-reported quality of life was maintained after surgery.

Jonathan E. Rosenberg of Memorial Sloan Kettering Cancer Center sits on the VOLGA steering committee. He called it the "first perioperative immunotherapy regimen where enfortumab vedotin-ejfv is administered only in the neoadjuvant setting." He said the regimen "has the potential to become a new standard of care in this curative-intent setting."

Dave Fredrickson, AstraZeneca's executive vice president for oncology hematology, called it the company's "third bladder cancer indication in two years." He said it reinforces Imfinzi as "an immunotherapy backbone."

About 16,000 patients will be treated for muscle-invasive bladder cancer in the United States in 2026. Roughly one in four bladder cancers is muscle-invasive, and as many as half of patients cannot take cisplatin.

For those patients, the historical standard was bladder-removal surgery alone, with high recurrence rates. Imfinzi is already approved in more than 50 countries for cisplatin-eligible disease, and VOLGA-regimen applications are under review in Europe and Japan.

A weekly injection for a rare disease

Klygefa treats adults with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. The approval covers patients positive for anti-acetylcholine receptor (AChR) antibodies, the immune markers that drive most cases.

Klygefa is the first and only dual-binding nanobody C5 inhibitor in the United States. It blocks C5, a complement protein in the immune attack, and also binds serum albumin, which extends its half-life.

That design allows once-weekly self-administration under the skin with an autoinjector. Its established C5 comparators, eculizumab and ravulizumab, are administered by infusion, so the pitch is convenience alongside efficacy.

What the PREVAIL trial showed

PREVAIL, a Phase III trial, enrolled 260 patients across 20 countries. Its primary endpoint measured change on the MG-ADL, a scale of daily-living function in myasthenia gravis, at week 26.

Klygefa beat placebo by 1.6 points on that scale, a statistically significant difference. Improvement was observed as early as week 1, and an open-label extension study is still running.

Treatment-emergent adverse events occurred at rates similar to placebo, and most were grade 1 or 2, the mild categories. The most common on Klygefa were injection-site reactions at 12%, back pain at 8% and vomiting at 5%.

AstraZeneca estimates about 98,500 people are diagnosed with gMG in the United States, about 81,000 of them AChR-positive. Those figures come from company data on file cited in the release.

Marc Dunoyer, chief executive of Alexion, called Klygefa a "first-of-its-kind treatment for gMG." He said it offers C5 efficacy "with the flexibility of once-weekly subcutaneous self-administration via autoinjector."

Kelly Gwathmey, a trial investigator, said gefurulimab delivered "rapid and sustained functional improvements with a once-weekly subcutaneous self-administered injection."

Klygefa is already approved in the European Union, Japan and other countries for certain adults. Submissions based on the PREVAIL results are under review in China and additional countries.

What remains unknown

United States launch timing and pricing for both products are unknown; neither release disclosed them. How quickly oncologists adopt a perioperative regimen, and how payers respond, is also unanswered.

Whether the VOLGA regimen wins approval in the European Union and Japan is undecided. Longer follow-up is also unknown: median overall survival was not reached, and the survival data come from a planned interim analysis.

Whether Klygefa's weekly self-injection wins patients from established infused C5 treatments is unproven. The open-label extension will show whether its early functional gains hold over longer treatment.

The decisions that come next

What to watch: regulatory decisions on the VOLGA regimen in the European Union and Japan, where applications are under review. AstraZeneca's launch disclosures should also reveal United States timing and pricing for both products.

Klygefa's review in China is the rare-disease test to follow. For Imfinzi, updated VOLGA survival follow-up will show whether the interim advantage holds as the data mature.

Sources & evidence

Source checked3 sources · 10 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 0.51 VOLGA event-free survival hazard ratio, Imfinzi combination vs comparator

    As of Nov. 16, 2026

  • 0.58 VOLGA overall survival hazard ratio, Imfinzi combination vs comparator

    As of Nov. 16, 2026

  • 695 VOLGA Phase III randomized patients

    As of Nov. 16, 2026

  • 64 VOLGA grade 3 or 4 adverse events, Imfinzi combination arm

    As of Nov. 16, 2026

  • 16000 United States patients treated for muscle-invasive bladder cancer in 2026

    As of Nov. 16, 2026

  • -1.6 PREVAIL MG-ADL treatment difference at week 26, Klygefa vs placebo

    As of Nov. 16, 2026

  • 260 PREVAIL Phase III enrolled patients

    As of Nov. 16, 2026

  • 98500 United States patients diagnosed with generalized myasthenia gravis

    As of Nov. 16, 2026

  • 12 Klygefa injection-site reactions in PREVAIL

    As of Nov. 16, 2026

  • 1500 FDA recommended durvalumab dosage, neoadjuvant phase

    As of Nov. 16, 2026

As of Monday, Nov. 16, 2026.

AstraZeneca

Stock · NYSE · AZN

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories